Breast Cancer

At 10-year follow-up, investigators observed similar outcomes with exemestane alone and sequential tamoxifen/exemestane in the phase 3 TEAM trial of postmenopausal women with hormone receptor (HR)-positive early breast cancer.
The results of a recent gene-sequencing analysis identify new pathogenic mutations associated with an increased risk for breast cancer.
The extended use of anastrozole for 3 years beyond 5 years of sequential therapy did not improve disease-free survival or overall survival in postmenopausal women with hormone receptor–positive, early breast cancer.
The addition of carboplatin increases response in patients with triple-negative breast cancer without pathogenic BRCA1 and BRCA2 mutations.
Prolonged use of hormonal contraceptives slightly increases the risk for breast cancer.
Intraventricular HER2 CAR T-cell therapy may be an option for patients with HER2+ breast cancer and brain metastasis.
Dr Matthew Goetz addresses common questions that arise when patients with HER+ metastatic breast cancer have progressed on a CDK4/6 inhibitor plus an aromatase inhibitor.
Dr Matthew Goetz believes that, as more mature data come into existence, the demonstration of a survival advantage will guide more patients with metastatic breast cancer to try CDK4/6 inhibitors plus aromatase inhibitors instead of chemotherapy.
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.
Dr Matthew Goetz addresses the prospect of utilizing CDK4/6 inhibitors to treat patients with HER2+ metastatic breast cancer, stating early data indicate that CDK4/6 inhibitors may have some antitumor activity in HER2+ breast cancer.
Page 2 of 18
Results 11 - 20 of 171